Regulatory round-up: 3 March 2026

Regulatory activity over the past week reflected steady committee throughput in Europe, a targeted oncology decision in the USA, and a cluster of safety and supply updates in the UK, Canada and Australia. No single agency dominated the cycle, but several decisions carry clear commercial and clinical implications.

The European Medicines Agency published outcomes from its February meeting of the Committee for Medicinal Products for Human Use, including multiple positive opinions and a small number of negative recommendations and withdrawals. In the USA, the US Food and Drug Administration continued to deploy expedited tools in oncology.

National regulators outside the EU focused largely on post-approval oversight. The UK regulator issued product quality and class-wide safety alerts, while Canada updated prescription status listings and flagged a scheduling proposal. Australia extended a substitution instrument linked to a statin shortage.